Monday, 5 December 2016

Novo Nordisk seeks EU and U.S. approval for new diabetes treatment

OSLO (Reuters) - Danish Novo Nordisk said on Monday it has filed for the European Union and the U.S. approval of semaglutide to treat adults with type 2 diabetes.


Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)